TABLE 2.
Gag-specific CTL responses in the Durban cohorts studied
| Best-recognized peptide | Subjecta | HLA class I type | CTL (per one million PBMCs) | Defined dominant epitope [HLA restriction] |
|---|---|---|---|---|
| p17c.4 | RCC-001 | A3/23 B49/5802 Cw6/- | 1,000 | RLRPGGKKK [A3] |
| RCC-002 | A*3001/66 B42/81 Cw4/17 | >1,000 | RLRPGGKKHYMIKHLVW [NDb] | |
| 338-M | A2/69 B7/42 Cw7/17 | >1,000 | RLRPGGKKHYMIKHLVW [ND] | |
| KEH04-M | A30/- B42/72 Cw2/17 | 354 | RLRPGGKKHYMIKHLVW [ND] | |
| p17c.7 | RCC-006 | A6801/- B62/71 Cw-/- | 600 | LVWASRELERFALNPGL [ND] |
| RCC-007 | ND | 1,000 | LVWASRELERFALNPGL [ND] | |
| p17c.11 | 338-M | A2/69 B7/42 Cw7/17 | >1,000 | IIKQLQPALQTGTEEL [ND] |
| p17c.13 | 338-M | A2/69 B7/42 Cw7/17 | >1,000 | SLYNTVATL [A2] |
| 325-M | A3/30 B*5802/72 Cw2/6 | >1,000 | ELRSLYNTVATLYCV [ND] | |
| 200-M | ND | 1,500 | ELRSLYNTVATLYCV [ND] | |
| KEH18-M | A*6802/- B44/*5802 Cw4/6 | 320 | ELRSLYNTVATLYCV [ND] | |
| p24c.3 | 994-M | A3/74 B57/62 Cw04/- | 760 | NAWVKVIEEKAFSPEVIPF [ND] |
| p24.5 | 1020-C5Y | A2/*3002 B14/*5802 Cw6/8 | 640 | TPQDLNTML [ND] |
| 1023-C6W | A24/30 B8/72 Cw2/7 | 540 | TPQDLNTML [ND] | |
| 021-M | A1/34 B72/81 Cw2/18 | >1,000 | SALSEGATPQDLNTMLNTVG [ND] | |
| 023-M | A29/3002 B7/42 Cw7/17 | >1,000 | SALSEGATPQDLNTMLNTVG [ND] | |
| 252-M | A29/*6802 B18/*5802 Cw5/6 | >1,000 | SALSEGATPQDLNTMLNTVG [ND] | |
| 270-M | A23/*6802 B41/71 Cw3/17 | >1,000 | SALSEGATPQDLNTMLNTVG [ND] | |
| 272-M | A30/34 B*5802/81 Cw6/18 | >1,000 | SALSEGATPQDLNTMLNTVG [ND] | |
| 298-M | A1/*6801 B*5802/81 Cw6/18 | >1,500 | SALSEGATPQDLNTMLNTVG [ND] | |
| 982-M | ND | >1,000 | TPQDLNTML [ND] | |
| 987-M | A2/*3002 B*5801/81 Cw04/- | >1,000 | TPQDLNTML [ND] | |
| 991-M | A1/*3002 B8/81 Cw7/18 | 980 | TPQDLNTML [ND] | |
| 1023-M | A2/24 B8/*5802 Cw6/7 | >1,000 | SALSEGATPQDLNTMLNTVG [ND] | |
| 1031-M | ND | >1,000 | TPQDLNTML [ND] | |
| KEH01-M | A30/68 B14/42 Cw8/17 | 380 | SALSEGATPQDLNTMLNTVG [ND] | |
| KEH02-M | A30/- B42/72 Cw2/17 | 900 | SALSEGATPQDLNTMLNTVG [ND] | |
| KEH19-M | A*3002/66 B42/*5802 Cw6/17 | 920 | TPQDLNTML [B42] | |
| p24c.16 | RC-005 | ND | 520 | NPPIPVDIYKRWII [ND] |
| 973-M | A1/3 B8/- Cw7/- | 1,860 | DIYKRWII [B8] | |
| p24c.17 | 1020-M | A2/- B*5802/62 Cw4/6 | 900 | GLNKIVRMY [ND] |
| p24c.20 | RCC-007 | ND | 1,000 | SILDIKQGPKEPFRDY [ND] |
| 109-M | A2/23 B72/- Cw2/- | 420 | SILDIKQGPKEPFRDY [ND] | |
| 188-M | A2/*6801 B18/*5802 Cw5/6 | 720 | SILDIKQGPKEPFRDY [ND] | |
| 260-M | ND | 173 | SILDIKQGPKEPFRDY [ND] | |
| p24c.22 | RCC-004 | A23/69 B-/- Cw3/18 | >1,000 | FRDYVDRFFKTLRAEQA [ND] |
| 022-M | A*3001/*3002 B42/45 Cw3/17 | 380 | FRDYVDRFFKTLRAEQA [ND] | |
| 270-M | A23/*6802 B41/71 Cw3/17 | >1,000 | FRDYVDRFFKTLRAEQA [ND] | |
| 971-M | A26/68 B8/71 Cw3/7 | 1,080 | FRDYVDRFFKTLRAEQA [ND] | |
| 1011-M | A*6802/74 B71/- Cw3/4 | 840 | FRDYVDRFFKTLRAEQA [ND] | |
| p24c.24 | RCC-004 | A23/69 B-/- Cw3/18 | >1,000 | QATQDVKNWMTDTLLV [ND] |
| p24c.25 | RC-007 | ND | 520 | WMTDTLLVQNANPDCKTI [ND] |
| p24c.28 | KEH14-M | A3/33 B71/72 Cw-/- | 340 | EEMMTACQGVGGPSHKARVL [ND] |
a
Subjects coded by a number followed by “M” represent adults in the cohort. All subjects were of the African racial group.
b
ND, not determined.